“Cash used by operating activities increased during the three months ended March 31, 2025 as a result of higher costs incurred for research and development and general and administrative primarily due to the Company’s acquisition of Exscientia.”10-Q · May 6, 2026 ↗
Recursion Pharmaceuticals, Inc.
RXRX
Market read
Recursion Pharmaceuticals, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 5 of 35 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 11 directly disclosed connections are confirming.
- At least 23 of 35 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ASAN begins moving with the group.
Invalidation: The live read weakens if participation falls to 12 of 35 members or fewer.
Research brief
The story so far
No new filing conclusion is available. 5 of 35 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 11 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- At least 23 of 35 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ASAN begins moving with the group.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +26.9% year over year.
- Operating margin changed -53.8 percentage points in the latest annual period.
- Net margin changed -75.3 percentage points in the latest annual period.
- Product pipeline and R&D has repeated adverse evidence across 4 filings.
- EV/sales is 57% below the available filing-peer median; determine whether growth and quality justify the difference.
Price as of Sep 10, 2026
3.16Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“For the three months ended March 31, 2026, the decrease relative to the three months ended March 31, 2025, was primarily driven by a decrease in salaries of $6.7 million as a result of headcount reductions in the year, in addition to one-time transaction cost…”10-Q · May 6, 2026 ↗
“Other Income (Loss), Net The following table summarizes our components of other income (loss), net: (in thousands, except percentages) Three months ended June 30, Change Six months ended June 30, Change 2025 2024 $ % 2025 2024 $ % Interest income 5,443 3,266…”10-Q · Aug 5, 2025 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 18.9× · EV/sales 9.0×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for RXRX. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for RXRX. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind RXRX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
MRKMerck & Co., Inc.partnerMay 6, 2026 ▾
“Merck KGaA, Darmstadt, Germany Research Collaboration Agreement In September 2023, we entered into a Research Collaboration Agreement, or the RCA, with the Healthcare Business of Merck KGaA, Darmstadt, Germany, referred to as Merck KGaA, Darmstadt, Germany, p…”
SNYSanofipartnerMay 6, 2026 ▾
“In AI-enabled chemistry, Sanofi and Recursion joint programs continue progressing toward development candidate designation and earlier-stage milestones over the next 12 months, including programs designed against challenging targets in immunology and oncology.”
Depended on by
RLYBRallybio CorporationinvesteeMar 16, 2026 ▾
“In July 2025, the Company entered into a definitive agreement to sell its interest in REV102, an Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 ("ENPP1") inhibitor in preclinical development for the treatment of patients with hypophosphatasia ("HPP"), to…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
RXRX is currently a Participant in the organic co-movement group Software Stocks. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.